US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

3.820 -0.050 (-1.29%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals (NASDAQ:IRWD) Highlights Minervini Trend Template and High Growth Momentum ↗
Via Chartmill
News headline image
Ironwood (IRWD) Q2 2026 Earnings Call Transcript ↗
LINZESS sales surged 14% as company raised full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Ironwood Pharmaceuticals Q2 Earnings Call Highlights ↗
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its... 
Via MarketBeat
Topics Earnings
Ironwood Pharmaceuticals (NASDAQ:IRWD) Raises Full-Year Guidance on Strong LINZESS Sales Despite Q2 Miss ↗
Via Chartmill
Ironwood Pharmaceuticals (NASDAQ:IRWD) Crushes Q1 Estimates with 97% LINZESS Surge ↗
Via Chartmill
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Reports Q4 Miss but Provides Robust 2026 Outlook ↗
Via Chartmill
News headline image
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Fits the Minervini High-Growth Momentum Trend Template ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals... 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Ironwood (IRWD) Q1 2026 Earnings Call Transcript ↗
Ironwood (IRWD) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Ironwood (IRWD) Q4 2025 Earnings Call Transcript ↗
Ironwood (IRWD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Stocks Trading Near $5 With Massive Earnings Upside ↗
Via MarketBeat
News headline image
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating ↗
Via MarketBeat
Discover the most active stocks in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >